Vo M, Jung S, Nguyen V, Tran V, Ruzimurodov N, Kim S
Heliyon. 2024; 10(6):e27892.
PMID: 38524535
PMC: 10957441.
DOI: 10.1016/j.heliyon.2024.e27892.
Dhodapkar M
Am J Hematol. 2022; 98 Suppl 2:S4-S12.
PMID: 36194782
PMC: 9918687.
DOI: 10.1002/ajh.26752.
Welters C, Lammoglia Cobo M, Stein C, Hsu M, Ben Hamza A, Penter L
Cancer Immunol Res. 2022; 10(11):1407-1419.
PMID: 36122410
PMC: 9627264.
DOI: 10.1158/2326-6066.CIR-22-0434.
Simmons G, Castaneda Puglianini O
Cancers (Basel). 2022; 14(17).
PMID: 36077787
PMC: 9455067.
DOI: 10.3390/cancers14174249.
Chung D, Sharma S, Rangesa M, DeWolf S, Elhanati Y, Perica K
Blood Adv. 2022; 6(5):1547-1558.
PMID: 35100339
PMC: 8905697.
DOI: 10.1182/bloodadvances.2021005941.
Harnessing the Immune System to Fight Multiple Myeloma.
Krejcik J, Barnkob M, Nyvold C, Larsen T, Barington T, Abildgaard N
Cancers (Basel). 2021; 13(18).
PMID: 34572773
PMC: 8467095.
DOI: 10.3390/cancers13184546.
Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?.
Minnie S, Hill G
Front Immunol. 2021; 12:651288.
PMID: 33777050
PMC: 7994609.
DOI: 10.3389/fimmu.2021.651288.
Treg and Oligoclonal Expansion of Terminal Effector CD8 T Cell as Key Players in Multiple Myeloma.
Joshua D, Vuckovic S, Favaloro J, Lau K, Yang S, Bryant C
Front Immunol. 2021; 12:620596.
PMID: 33708212
PMC: 7940512.
DOI: 10.3389/fimmu.2021.620596.
Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients.
Vuckovic S, Bryant C, Lau K, Yang S, Favaloro J, McGuire H
Blood Adv. 2020; 4(19):4593-4604.
PMID: 32986791
PMC: 7556150.
DOI: 10.1182/bloodadvances.2020002237.
T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.
Janelle V, Rulleau C, Del Testa S, Carli C, Delisle J
Front Immunol. 2020; 11:276.
PMID: 32153583
PMC: 7046834.
DOI: 10.3389/fimmu.2020.00276.
Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
Ria R, Vacca A
Int J Mol Sci. 2020; 21(2).
PMID: 31963513
PMC: 7013615.
DOI: 10.3390/ijms21020613.
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
Cohen A, Raje N, Fowler J, Mezzi K, Scott E, Dhodapkar M
Clin Cancer Res. 2019; 26(7):1541-1554.
PMID: 31672768
PMC: 8176627.
DOI: 10.1158/1078-0432.CCR-19-2111.
The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
Feinberg D, Paul B, Kang Y
Cell Immunol. 2019; 345:103964.
PMID: 31492448
PMC: 6832886.
DOI: 10.1016/j.cellimm.2019.103964.
T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
Biernacki M, Brault M, Bleakley M
Cancer J. 2019; 25(3):179-190.
PMID: 31135525
PMC: 6540815.
DOI: 10.1097/PPO.0000000000000378.
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
Bailur J, McCachren S, Doxie D, Shrestha M, Pendleton K, Nooka A
JCI Insight. 2019; 5.
PMID: 31013254
PMC: 6629164.
DOI: 10.1172/jci.insight.127807.
Activated Allogeneic Donor-derived Marrow-infiltrating Lymphocytes Display Measurable In Vitro Antitumor Activity.
Biavati L, Noonan K, Luznik L, Borrello I
J Immunother. 2019; 42(3):73-80.
PMID: 30829726
PMC: 9289952.
DOI: 10.1097/CJI.0000000000000256.
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy.
Ravi R, Noonan K, Pham V, Bedi R, Zhavoronkov A, Ozerov I
Nat Commun. 2018; 9(1):741.
PMID: 29467463
PMC: 5821872.
DOI: 10.1038/s41467-017-02696-6.
Chimeric antigen receptor T-cell therapies for multiple myeloma.
Mikkilineni L, Kochenderfer J
Blood. 2017; 130(24):2594-2602.
PMID: 28928126
PMC: 5731088.
DOI: 10.1182/blood-2017-06-793869.
Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments.
Goodyear O, Essex S, Seetharam A, Basu S, Moss P, Pratt G
Oncotarget. 2017; 8(18):30383-30394.
PMID: 28389623
PMC: 5444750.
DOI: 10.18632/oncotarget.16628.
Systematic evaluation of immune regulation and modulation.
Stroncek D, Butterfield L, Cannarile M, Dhodapkar M, Greten T, Grivel J
J Immunother Cancer. 2017; 5:21.
PMID: 28331613
PMC: 5359947.
DOI: 10.1186/s40425-017-0223-8.